Suberoyl bishydroxamic acid-induced apoptosis in HeLa cells via ROS-independent, GSH-dependent manner

Molecular Biology Reports

Volumn 40, Issue 5, 2013, Pages 3807-3816

  You, Bo Ra ^a   Park, Woo Hyun ^a  

^a Chonbuk National University   (South Korea)

Author keywords

Apoptosis; Caspase; HeLa; Histone deacetylase; Suberoyl bishydroxamic acid

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; ASCORBIC ACID; CASPASE 3; CASPASE 8; CASPASE INHIBITOR; GLUTATHIONE; HISTONE DEACETYLASE INHIBITOR; LIPOCORTIN 5; REACTIVE OXYGEN METABOLITE; SUBEROYLBISHYDROXAMIC ACID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL GROWTH; CELL LEVEL; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IC 50; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN FUNCTION; UTERINE CERVIX CANCER;

ACETYLCYSTEINE; APOPTOSIS; ASCORBIC ACID; BUTHIONINE SULFOXIMINE; CASPASE INHIBITORS; CELL PROLIFERATION; GLUTATHIONE; HELA CELLS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MEMBRANE POTENTIAL, MITOCHONDRIAL; REACTIVE OXYGEN SPECIES;

EID: 84878410730     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-2459-1     Document Type: Article

References (33)

1. Burgess DJ (2012) Cancer genomics: histone modification at the gene level. Nat Rev Genet 13(3):148-149. doi: 10.1038/nrg3181nrg3181
2. Burgess DJ (2012) Histone modification at the gene level. Nat Rev Cancer 12(3):156. doi: 10.1038/nrc3233nrc3233
3. Ganesan A, Nolan L, Crabb SJ, Packham G (2009) Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery. Curr Cancer Drug Targets 9(8):963-981
4. Shukla V, Vaissiere T, Herceg Z (2008) Histone acetylation and chromatin signature in stem cell identity and cancer. Mutat Res 637(1-2):1-15. doi: 10.1016/j.mrfmmm.2007.07.012
5. Suzuki J, Chen YY, Scott GK, Devries S, Chin K, Benz CC, Waldman FM, Hwang ES (2009) Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res 15(9):3163-3171. doi: 10.1158/1078-0432.CCR-08-2319
6. Stilling RM, Fischer A (2011) The role of histone acetylation in age-associated memory impairment and Alzheimer's disease. Neurobiol Learn Mem 96(1):19-26. doi: 10.1016/j.nlm.2011.04.002S1074-7427(11)00064-5
7. Sayyed SG, Gaikwad AB, Lichtnekert J, Kulkarni O, Eulberg D, Klussmann S, Tikoo K, Anders HJ (2010) Progressive glomerulosclerosis in type 2 diabetes is associated with renal histone H3K9 and H3K23 acetylation, H3K4 dimethylation and phosphorylation at serine 10. Nephrol Dial Transplant 25(6):1811-1817. doi: 10.1093/ndt/gfp730
8. Spiegel S, Milstien S, Grant S (2012) Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 31(5):537-551. doi: 10.1038/onc.2011.267onc2011267
9. Kanai Y (2008) Overexpression of HDACs: a prognostic marker for gastric cancer identified by tissue microarray. Lancet Oncol 9(2):91-93. doi: 10.1016/S1470-2045(08)70012-3
10. Wang L, Zou X, Berger AD, Twiss C, Peng Y, Li Y, Chiu J, Guo H, Satagopan J, Wilton A, Gerald W, Basch R, Wang Z, Osman I, Lee P (2009) Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res 1(1):62-71
11. Lehmann A, Denkert C, Budczies J, Buckendahl AC, Darb-Esfahani S, Noske A, Muller BM, Bahra M, Neuhaus P, Dietel M, Kristiansen G, Weichert W (2009) High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer 9:395. doi: 10.1186/1471-2407-9-395
12. Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27(32):5459-5468. doi: 10.1200/JCO.2009.22.1291
13. Pettazzoni P, Pizzimenti S, Toaldo C, Sotomayor P, Tagliavacca L, Liu S, Wang D, Minelli R, Ellis L, Atadja P, Ciamporcero E, Dianzani MU, Barrera G, Pili R (2011) Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells. Free Radic Biol Med 50(2):313-322. doi: 10.1016/j.freeradbiomed.2010.11.011
14. Phillip CJ, Giardina CK, Bilir B, Cutler DJ, Lai YH, Kucuk O, Moreno CS (2012) Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells. BMC Cancer 12(1):145. doi: 10.1186/1471-2407-12-145
15. Sweet MJ, Shakespear MR, Kamal NA, Fairlie DP (2012) HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation. Immunol Cell Biol 90(1):14-22. doi: 10.1038/icb.2011.88icb201188
16. Gong K, Xie J, Yi H, Li W (2012) CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochem J 443(3):735-746. doi: 10.1042/BJ20111685
17. Morgan MJ, Liu ZG (2010) Reactive oxygen species in TNFalpha-induced signaling and cell death. Mol Cells 30(1):1-12. doi: 10.1007/s10059-010-0105-0
18. Duenas-Gonzalez A, Lizano M, Candelaria M, Cetina L, Arce C, Cervera E (2005) Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer 4:38. doi: 10.1186/1476-4598-4-38
19. Anton M, Horky M, Kuchtickova S, Vojtesek B, Blaha O (2004) Immunohistochemical detection of acetylation and phosphorylation of histone H3 in cervical smears. Ceska Gynekol 69(1):3-6
20. Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, Raju GC, Hooi SC (2005) Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 12(4):395-404. doi: 10.1038/sj.cdd.4401567
21. Flis S, Gnyszka A, Splawinski J (2009) HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines. Biochem Biophys Res Commun 387(2):336-341. doi: 10.1016/j.bbrc.2009.07. 017
22. You BR, Park WH (2010) Suberoyl bishydroxamic acid inhibits the growth of A549 lung cancer cells via caspase-dependent apoptosis. Mol Cell Biochem 344(1-2):203-210. doi: 10.1007/s11010-010-0543-1
23. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, Kim BK, Lee YY (2000) Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 60(11):3065-3071
24. Han YH, Kim SZ, Kim SH, Park WH (2008) Apoptosis in pyrogallol-treated Calu-6 cells is correlated with the changes of intracellular GSH levels rather than ROS levels. Lung Cancer 59(3):301-314. doi: 10.1016/j.lungcan.2007.08.034
25. Park WH, Han YH, Kim SH, Kim SZ (2007) Pyrogallol, ROS generator inhibits As4.1 juxtaglomerular cells via cell cycle arrest of G2 phase and apoptosis. Toxicology 235(1-2):130-139. doi: 10.1016/j.tox.2007.03.018
26. Han YH, Kim SZ, Kim SH, Park WH (2007) Arsenic trioxide inhibits growth of As4.1 juxtaglomerular cells via cell cycle arrest and caspase-independent apoptosis. Am J Physiol Renal Physiol 293(2):F511-F520. doi: 10.1152/ajprenal.00385.2006
27. Han YH, Kim SH, Kim SZ, Park WH (2008) Caspase inhibitor decreases apoptosis in pyrogallol-treated lung cancer Calu-6 cells via the prevention of GSH depletion. Int J Oncol 33(5):1099-1105
28. Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, Jaulin C (2009) Histone deacetylase inhibitors and genomic instability. Cancer Lett 274(2):169-176. doi: 10.1016/j.canlet.2008.06.005
29. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, Marks PA (2005) Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102(3):673-678. doi: 10.1073/pnas.0408732102
30. Miriyala S, Spasojevic I, Tovmasyan A, Salvemini D, Vujaskovic Z, St Clair D, Batinic-Haberle I (2012) Manganese superoxide dismutase, MnSOD and its mimics. Biochim Biophys Acta 1822(5):794-814. doi: 10.1016/j.bbadis.2011.12.002
31. Schnelldorfer T, Gansauge S, Gansauge F, Schlosser S, Beger HG, Nussler AK (2000) Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells. Cancer 89(7):1440-1447. doi: 10.1002/1097-0142(20001001)89:7<1440:AID-CNCR5>3.0.CO;2-0
32. Brechbuhl HM, Kachadourian R, Min E, Chan D, Day BJ (2012) Chrysin enhances doxorubicin-induced cytotoxicity in human lung epithelial cancer cell lines: the role of glutathione. Toxicol Appl Pharmacol 258(1):1-9. doi: 10.1016/j.taap.2011.08.004
33. Fath MA, Ahmad IM, Smith CJ, Spence J, Spitz DR (2011) Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism. Clin Cancer Res 17(19):6206-6217. doi: 10.1158/1078-0432.CCR-11-0736